SynthesisScientific reports2024

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.

Renuka Suvarna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.